About: Effects of MS disease-modifying therapies on responses to vaccinations: a review.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of MS disease-modifying therapies on responses to vaccinations: a review. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effects of MS disease-modifying therapies on responses to vaccinations: a review.
Creator	Ciotti, John Cross, Anne Valtcheva, Manouela
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: : Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from these studies have important implications for people with multiple sclerosis who require vaccination and are using disease-modifying therapies. METHODS: : Searches using PubMed and other engines were conducted in May 2020 to collect studies evaluating the impact of various disease-modifying therapies on immune responses to vaccination. RESULTS: : Several studies demonstrated preserved immune responses in people treated with beta-interferons to multiple vaccine types. Limited data suggest vaccine responses to be preserved with dimethyl fumarate treatment, as well. Vaccine responses were reduced to varying degrees in those treated with glatiramer acetate, teriflunomide, sphingosine-1-phosphate receptor modulators, and natalizumab. The timing of vaccination played an important role in those treated with alemtuzumab. Humoral vaccine responses were significantly impaired by B cell depleting anti-CD20 monoclonal antibody therapies, particularly to a neoantigen. Data are lacking on vaccine responses in patients with multiple sclerosis taking cladribine and high-dose corticosteroids. Notably, the majority of these studies have focused on humoral responses, with few examining cellular immune responses to vaccination. CONCLUSIONS: : Prior investigations into the effects of individual disease-modifying therapies on immune responses to existing vaccines can serve as a guide to expected responses to a SARS-CoV-2 vaccine. Responses to any vaccination depend on the vaccine type, the type of response (recall versus response to a novel antigen), and the impact of the individual disease-modifying therapy on humoral and cellular immunity in response to that vaccine type. When considering a given therapy, clinicians should weigh its efficacy against MS for the individual patient versus potential impact on responses to vaccinations that may be needed in the future.
has issue date	2020-08-01(xsd:dateTime)
bibo:doi	10.1016/j.msard.2020.102439
bibo:pmid	32769063
has license	no-cc
sha1sum (hex)	f4bba64e8ad9bf22fb18cfc63135cec68f611603
schema:url	https://doi.org/10.1016/j.msard.2020.102439
resource representing a document's title	Effects of MS disease-modifying therapies on responses to vaccinations: a review.
has PubMed Central identifier	PMC7395588
has PubMed identifier	32769063
schema:publication	Mult Scler Relat Disord
resource representing a document's body	covid:f4bba64e8ad9bf22fb18cfc63135cec68f611603#body_text
is schema:about of	named entity 'therapies' named entity 'Journal' named entity 'disease-modifying' named entity 'delayed type hypersensitivity' named entity 'influenza' named entity 'neurologic' named entity 'vaccine' named entity 'control group' named entity 'controlled study' named entity 'vaccination' named entity 'control group' named entity 'antibody response' named entity 'siponimod' named entity 'antigen' named entity 'control group' named entity 'influenza vaccination' named entity 'polio' named entity 'natalizumab' named entity '2009 H1N1 pandemic' named entity 'H1N1' named entity 'vaccine' named entity 'influenza' named entity 'rituximab' named entity 'disease-modifying' named entity 'human papillomavirus' named entity 'titer' named entity 'antibodies' named entity 'MCV4' named entity 'meningococcal conjugate vaccine' named entity 'disability' named entity 'observational study' named entity 'influenza vaccine' named entity 'ocrelizumab' named entity '28 days' named entity 'recombinant vector' named entity 'randomized study' named entity 'vaccination' named entity 'corticosteroids' named entity 'statistically significant' named entity 'beta-interferon' named entity 'rheumatoid arthritis' named entity 'vaccine' named entity 'influenza vaccination' named entity 'immunization' named entity 'influenza' named entity 'humoral response' named entity 'natalizumab' named entity 'IgM' named entity 'systemic lupus erythematosus' named entity 'beta-interferon' named entity 'influenza' named entity 'cladribine' named entity 'H1N1' named entity 'fingolimod' named entity 'teriflunomide' named entity 'live attenuated vaccines' named entity 'antibody' named entity '2015/2016' named entity 'vaccination' named entity 'interferons' named entity 'Multiple sclerosis' named entity 'placebo group' named entity 'neoantigens' named entity 'serotypes' named entity 'antigen' named entity 'immunization' named entity 'KLH' named entity 'ClinicalTrials.gov' named entity 'immune responses' named entity 'diphtheria' named entity 'siponimod' named entity 'vaccination' named entity 'rubella' named entity 'placebo' named entity 'DMT' named entity 'hemagglutination inhibition' named entity 'Level 4' named entity 'contraindicated' named entity 'immunizations'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software